1. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
- Author
-
Fang, Kailu, Wang, Hong-liang, Lin, Yushi, Zheng, Luyan, Li, Shuwen, and Wu, Jie
- Subjects
- *
PREVENTIVE medicine , *QUALITY-adjusted life years , *COST effectiveness , *DEATH , *HEALTH policy , *DECISION making , *DESCRIPTIVE statistics , *ANTIVIRAL agents , *RESEARCH , *MEDICAL screening , *PUBLIC health , *CHRONIC hepatitis C , *MEDICAL care costs - Abstract
China has the largest number of hepatitis C virus (HCV) infection in the world, but current levels of diagnosis and treatment are low. The objective of this study was to assess the cost-effectiveness of various universal HCV screening and treatment strategies in China and inform decisions on health policy. A cost-effectiveness analytical study. We developed a Markov model to investigate cost-effectiveness of different HCV screening and treatment strategies in China. We simulated several screening scenarios for Chinese people aged 18–70 years. We estimated incremental cost-effectiveness ratios (ICERs) of different intervention scenarios compared with status quo. Expanded HCV screening and treatment strategy with prioritisation for high-risk groups (Scenario S5) was the most cost-effective strategy (ICER: USD $11,667.71/quality-adjusted life-year [QALY] gained), which resulted in great reduction in HCV-related diseases and deaths, with a 67.11% reduction in cases of chronic HCV. Universal HCV screening and treatment implementation remains a cost-effective strategy when delayed until 2025 (ICER: USD $17,093.69/QALY), yet the delayed strategy is less effective in reducing HCV-related deaths. Expanded HCV screening and treatment strategy with prioritisation for high-risk groups is the most cost-effective strategy and has lead to a significant reduction in both HCV morbidity and mortality in China, which would essentially eliminate HCV as a public threat. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF